Roche announces that it is pledging further funding for the Roche Organ Transplantation Research Foundation (ROTRF) until 2008. With an annual donation of over CHF 5 million, Roche is reinforcing a long-term commitment to transplantation research that aims to improve the lives of thousands of patients living with transplanted organs every year.

William M Burns, Head of Roche's Pharmaceuticals Division, said: "Roche is committed to exploring new research concepts that help to deliver the best possible care for people living with transplanted organs. Our decision to extend our financial support to the Foundation reflects Roche's continued commitment to the transplantation community and to innovation in scientific research. We are proud of our association with this pioneering Foundation."

Prof Phil Halloran, Chair of the Board of Trustees, said: "Innovation holds the key to improving the lives of people living with an organ transplant. It is always a challenge to secure funding for scientific research and Roche's support means that ROTRF is able to continue to fund and develop cutting-edge research worldwide. Ultimately, this helps advance our knowledge in transplantation and save lives."

ROTRF is a not-for-profit research foundation, whose remit to support ground-breaking research projects attracts new researchers with innovative scientific ideas, who aim to tackle areas of unmet medical need in organ transplantation. The first grants of this year have been awarded to nine scientists from around the world including Australia, Canada, Germany, UK and USA. Exceptionally, in 2003, almost half of the 89 applicants for research grants were from Europe.

New grants in 2003 focus on the need to further our understanding of the processes underlying chronic and acute rejection, to improve long-term graft survival. The objective of transplantation immunology is to specifically inhibit the body's response to the graft while leaving the re
'"/>

Contact: Lisa Marriott
lisa.marriott@ketchum.com
020-7611-3691
Ketchum
22-Sep-2003

Page: 1 2 3
Related medicine news :

1. Rochester, BCM test bird-flu vaccine in humans
2. Roche files marketing application for Avastin with European health authorities
3. Rochester chosen to focus on rare neurological diseases
4. New rapid anthrax test developed through collaboration between Mayo Clinic and Roche Diagnostics. Test, which provides results in less than one hour, will be made available to United States laboratories
5. University of Rochester awarded patent for class of drugs known as cox-2 inhibitors
6. NYU/U. Rochester team find neurons in visual cortex adapt to images within .5 seconds of viewing
7. Virginity pledges do not reduce STD risk: May encourage high risk sexual behavior
8. Senator Jon S. Corzine pledges support to NYU Child Study Center
9. Frank family pledges $10 million to support education of physician-scientists at the University of Chicago
10. Study finds continued reduction in breast cancer incidence associated with longer use of raloxifene
11. Anthrax survivors continued to have health problems one year after exposure